YOKNEAM, Israel, Aug. 6, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences and events in August:
9th Annual Needham Virtual MedTech & Diagnostics Conference
Presenters: Moshe Mizrahy, Chief Executive Officer and Yair Malca, Chief Financial Officer
Format: Virtual one-on-one meetings
When: Monday, Aug. 12
Canaccord 44th Annual Global Growth Conference
Presenters: Yair Malca, Chief Financial Officer
Format: In-person fireside chat moderated by Caitlin Cronin, Director of MedTech Equity Research, and meetings
When: Wednesday, Aug. 14 at 2:00 pm ET
A live webcast of the presentation can be accessed here.
About InMode
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.
Investor Relations Contact:
Miri Segal-Scharia
MS-IR LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
917-607-8654
| Last Trade: | US$14.59 |
| Daily Change: | -0.35 -2.34 |
| Daily Volume: | 195,971 |
| Market Cap: | US$922.230M |
September 02, 2025 July 30, 2025 April 28, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
